177Lu-Zoledronic acid (177Lu-ZLD, 177Lu-Zoledronate) is a new class of bisphosphonate developed in Iran at the University of Tehran. 177Lu-ZLD is a derivative of zoledronic acid, a drug that has already proven efficacy in several phase III studies and showed efficacy in the treatment of bone metastases secondary to all solid tumor types and bone lesions from multiple myeloma. This molecule has also been explored labeled with both 47Sc and 177Lu at the Institute of Nuclear Chemistry and Technology in Warsaw, Poland. The molecule was developed at the Mainz University and is patent protected. ITG obtained an exclusive license for its development.
177Lu-Zoledronic acid is a new class of therapeutic agent for metastasized prostate cancer. As a bone tissue seeking agent it will be primarily efficient for bone metastases. The drug is expected to work as an efficient pain palliation agent in all cancers progressing in bone metastases, and could improve OS in these patients.
177Lu-Zoledronic acid is at an early stage of development and just in a first stage of trial in human. The first clinical data out of South Africa have been published in 2016. Binding studies and preclinical data have shown superiority of 177Lu-ZLD over 153Sm-EDTMP and 166Ho-DOTMP.